HK Stock Market Move | MEDBOT-B(02252) rises more than 4%, Siasun Robot&Automation plans to install at least 200 units of 26-year-old map surgery, the overseas market remains the core growth engine.

MEDBOT-B (02252) rose more than 4% as of the time of publication, up 3.44% to HK $28.28, with a turnover of HK $42.4415 million. On the news front, JP Morgan released a research report pointing out that MEDBOT-B's fiscal year 2026 guidance marks a clear shift from "commercial validation" to "profit release," with management setting clear revenue, profit, and cash flow targets. The company expects revenue of approximately RMB 1.1 billion this year, nearly doubling year-on-year, while achieving a balance between net profit and losses to profits, as well as positive free cash flow, indicating entry into the operational leverage phase. The bank stated that as of early April, the company had installed 23 TiMi Surgery Siasun Robot & Automation Systems and held 86 orders in hand. The management guided that they will install approximately 103 to 113 units in the first half of the year, at least 200 units for the whole year, and indicated that the delivery bottleneck in the second half of last year has been resolved. The overseas market will continue to be the core growth engine, with demand covering Europe, Asia (excluding China), and Latin America.